The invention provides a prognosis evaluation system for a prostate cancer patient and application of the prognosis evaluation system, and relates to the technical field of biomedicine. The evaluationsystem includes detecting a system of 14 sets of immune-related signature genes and a PCIPI. The 14 sets comprise: aDC, Angiogensis, CSF1 Response, GRANS, HCK, Lymphocyte-Specific Attractor, Neutrophils, NK CD56 bright cells, NK CD56 dim cells, Macrophages, Pro-inflammatory, Proliferation, Stromal cell, and ZMYND10 Metagene. According to the invention, the defects of the prior art are overcome, the PCIPI is established, and the correlation between the PCIPI and the recurrence-free lifetime (RFS) of a patient, tumor-infiltrated immune cells and mutation load is determined, so that the potential mechanism of immunotherapy drug resistance generation can be explained, and the clinical treatment of the prostate cancer patient can be guided conveniently.